Cantel Medical (CMN) Tops Q3 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
Piper Jaffray Raises Price Target on Cantel Medical (CMN) Following 3Q15
June 10, 2015 8:21 AM EDTPiper Jaffray reiterates an Overweight rating on Cantel Medical (NYSE: CMN), and raised the price target to $60.00 (from $49.00), following 3Q15. CMN reported sales of $141.5M, which was $5.5M above forecast. Earnings were $0.35, 2 cents above estimates.
Analyst Thomas Gunderson commented, "Strong sales growth of 18% was led by the Endoscopy (up 35%) and Water Purification... More
